Chen, Mingyi

PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 553

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 285

Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 173

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade

Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 141

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Zhang, W., Tong, S., Hu, B., Wan, T., Tang, H., Zhao, F., Jiao, T., Li, J., Zhang, Z., Cai, J., et al. (2023) · Journal for ImmunoTherapy of Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 136

Deep learning in digital pathology for personalized treatment plans of cancer patients

Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 34